Objective: Cognitive decline is a hallmark of dementia; however, the brain epigenetic 49 signature of cognitive decline is unclear. We investigated the associations between brain 50 tissue-based DNA methylation and cognitive trajectory. 51
Abstract

Introduction 72
Cognitive decline is a common concern among older adults; however, the trajectory of 73 cognitive performance with age has a wide range from stable to rapid decline. Cognitive 74 trajectory is an important predictor of health outcomes and mortality, independent of other 75 commonly assessed risk factors 1 . Dementia is a common consequence of a decline in 76 cognition, and Alzheimer Disease (AD) is its leading cause 2 . AD is characterized by the 77 neuropathological accumulation of neuritic plaques and neurofibrillary tangles, which is 78 accompanied by neuronal loss 3 ; however, most older individuals have several co-occurring 79 neuropathologies. Collectively, neuropathologies explain about 40% of the variance in 80 cognitive trajectory, leaving most unexplained 4,5 . Thus, cognitive trajectory may be 81 considered a summation of the different neuropathological and biological processes 82 independent of pathologies at work in the aging human brain 5-7 . 83 Despite the importance of understanding cognitive trajectory, existing epigenetic work 84 on DNA methylation levels measured in brain tissue has primarily focused on AD-specific 85 pathologies [8] [9] [10] [11] and clinical diagnosis of AD [12] [13] [14] . In contrast, epigenetic studies that focused 86 on examining cognitive decline were limited due to measuring DNA methylation changes in 87 blood 15 , which showed only moderate correlations (~0.4) with brain methylation 15 . Thus, 88 there is need to understand the epigenetic changes that are associated with cognitive trajectory 89 to identify potential mechanisms that may act through or independent of known 90 neuropathologies. 91
In this study, we investigated the associations between brain tissue-based DNA 92 methylation and cognitive trajectory in 636 participants from the Religious Order Study and 93 Rush Memory and Aging Project (ROS/MAP) cohorts. Cognitive trajectory was assessed in 94 five cognitive domains (episodic memory, perceptual speed, perceptual orientation, semantic kernel procedure that allows to investigate associations between multiple predictors (e.g. 97 methylation sites in a gene) with multiple outcomes (e.g. multiple cognitive domains) 16, 17 . 98
Findings were validated in independent post-mortem frontal cortex samples 10 , and their 99 biological plausibility were evaluated using gene expression and genotype data. 100 101
Methods 102
Study design and study population 103
The discovery dataset included deceased subjects from two large, prospectively 104 followed cohorts recruited by investigators at Rush Alzheimer's Disease Center in Chicago, 105 IL: The Religious Orders Study (ROS) and the Rush Memory and Aging Project (MAP) 11, 18 . 106
Both ROS and MAP collect detailed annual cognitive and clinical evaluations, and brain 107 autopsy. Participants provided informed consent, an Anatomic Gift Act for organ donation, 108 and a repository consent to allow their data to be repurposed. Both studies were approved by 109 an Institutional Review Board of Rush University Medical Center. To be included in the 110 present study, participants must have at least two follow-up evaluations, and available 111 methylation data derived from dorsolateral prefrontal cortex. As in previous publications, the 112 ROS and MAP data were analyzed jointly since much of the phenotypic data collected are 113 identical at the item level in both studies and collected by the same investigative team 11, 19 . 114
The replication dataset included samples from the MRC London Neurodegenerative 115 Disease Brain Bank (GSE59685) 10 . 116
117
DNA methylation 118
In the discovery dataset, DNA methylation was measured from the dorsolateral 119 prefrontal cortex (dPFC; Broadman area 46) as previously described in 737 ROS/MAP 6 participant samples 11 , of which 665 had complete phenotype and covariate information. DNA 121 was extracted from cortically dissected sections of dPFC and DNA methylation was measured 122 using the Illumina HumanMethylation450 Beadchip array. Initial data processing, including 123 color channel normalization and background removal, was performed using the Illumina 124 GenomeStudio software. The raw IDAT files were obtained from Synapse 125 (www.synapse.org; Synapse ID: syn7357283) and the following probes were removed: 1) 126 probes with a detection p-value > 0.01 in any sample, 2) probes annotated to the X and Y 127 chromosomes by Illumina, 3) probes that cross-hybridize with other probes due to sequence 128 similarity (identified by 20 ), 3) non-CpG site probes, and 4) probes that overlap with common 129 SNPs (identified by 21 ). After this filtering, the remaining CpG sites were normalized using 130 the BMIQ algorithm in Watermelon R package 22 , and the ComBat function from the sva R 131 package was used to adjust for batch effects 23 . CpG sites with a distance of more than 20 KB 132 to the closest gene were excluded from analysis. After quality control 338,036 discrete CpG 133 dinucleotides corresponding to 26,558 genes in 636 subjects were used for analysis. 134
In the replication dataset, DNA methylation was derived from prefrontal cortex 135 obtained from individuals archived in the Medical Research Counsil (MRC) London 136
Neurodegenerative Disease Brain Bank. This previously published dataset provided samples 137 with DNA methylation data measured on the Illumina HumanMethylation450 Beadchip array. 138
Data was obtained from the Gene Expression Omnibus (GEO; GSE59685) 10 . Similar to above 139 probes annotated to the X and Y chromosomes, cross-hybridizing probes, non-CpG site 140 probes and probes that overlap with common SNP were removed. The data downloaded from 141 GEO was already normalized using the dasen algorithm in Watermelon R package 22 and then 142 the ComBat function from the sva R package was used to adjust for array ID batch effects 23 . 143
Neuronal and non-neuronal brain cell-type proportions were estimated and normalized 144 between PFC samples 24 . CpG sites with a distance of more than 20 KB to the closest gene 7 were excluded from analysis. After quality control 358,515 discrete CpG dinucleotides 146 corresponding to 27,585 genes in 66 subjects were used for analysis. 147 148
Genotype data 149
Genotyping data was generated using two microarrays, Affymetrix GeneChip 6.0 150 (Affymetrix, Inc, Santa Clara, CA, USA ) and Illumina HumanOmniExpress (Illumina, Inc, 151
San Diego, CA, USA) as described previously 25 . Genotyping was imputed to the 1000 152 Genome Project Phase 3 using the Michigan Imputation Server 26 , and the following filtering HiSeq with 101-bp paired-end reads using the strand-specific dUTP method with poly-A 159 selection with a coverage of 50 million reads. BAM files were converted to FASTQ format 160 using Picard, followed by alignment of reads to GRCh38 reference genome using STAR 27 . 161
Gene level counts were computed using STAR 27 . Genes with < 1 count per million in at least 162 50% of the samples and with missing length and percent GC content were removed. 163
Additionally, two outlier samples were removed. After quality control, counts were 164 normalized using variance stabilization transformation, which performed log 2 transformation 165 of the counts, normalizes for library size, and transforms the counts to approximately 166 homoscedastic 28 . Then the candidate mRNAs were extracted for association analysis with 167 rate of cognitive decline adjusting for sex, age at death, RIN, PMI, RNA-sequencing batch, 168 and cell type composition. Proportions of neurons, astrocytes, oligodendrocytes, and 169 microglia were estimated from RNA-sequencing data using CIBERSORT 29 and cell-type 170 specific signatures 30 . We used the proportions of cell type to adjust for tissue heterogeneity. 171
Using the findings of the epigenome-wide association study of cognitive trajectory, we 172 selected the transcripts corresponding to the associated genes for further analyses after the 173 aforementioned quality control and variance stabilization transformation. In our main analysis, we estimated epigenetic associations across five neurocognitive 200 domains in a gene-based analysis, in which each CpG site was assigned to the closest gene 201 using the Bioconductor package hiAnnotator 34 and the ensembl gene predictions (ensGene, 202 version of Apr-06-2014). All CpG sites with a distance of no more than 20 KB to the closest 203 gene, were included in the analyses. In addition, we conducted a sensitivity analysis in which 204 we only included CpG sites with a distance of no more than 10 KB to the closest gene. In a 205 traditional association study of cognitive trajectory, each cognitive test may be either tested 206 individually 15 or used to estimate a composite measure aggregated across several cognitive 207 tests 35 . However, these approaches are underpowered in the presence of pleiotropy since they 208 fail to exploit correlation among domains 17 . Thus, analysis of a single composite measure can 209 lose power if the causal CpG sites are only associated with a subset of the features that make 210 the composite measure 17 . Hence, it can be more powerful to directly account for the trait 211 correlations using kernel methods 36 . Kernel methods quantify the genetic similarity among 212 pairs of subjects and test whether this genetic similarity is associated with trait similarity. 213 Thus, they harness potential pleiotropy that exists between traits to improve power to detect 214 associations. To analyze epigenetic associations across five neurocognitive domains 215 simultaneously, we applied a variation of the GAMuT test 16 that was adapted to DNA 216 methylation data. GAMuT is motivated by the idea that individuals with similar epigenetic 217 patterns should also have similar cognitive traits across the different cognitive domains. 218 Consequently, GAMuT constructs two different similarity matrices; one similarity matrix 219 including cognitive decline in the five cognitive domains and the other similarity matrix for 220 the epigenetic variation (beta values of CpG sites) assigned to a gene. Phenotypic and 221 epigenetic similarity were modelled using linear kernels. P-values for GAMuT were derived 222 using Davies' exact method, which is a computationally efficient method to provide accurate 223 p-values in the extreme tails of tests that follow mixtures of chi-square variables 37,38 . To test 224 which cognitive domains and CpG sites were likely main drivers in our multivariate analysis, 225
we conducted an association analysis for each domain separately. The gene-based analyses for 226 the single domains were performed with GAMuT and linear regression analyses were used in 227 the CpG-based analyses. 228
All association models were adjusted for age at death, education, sex, ancestry, 229 smoking status and post-mortem interval (PMI). Principal components (PCs) based on CpG 230 sites chosen for their potential to proxy nearby SNPs (within 10 BP) were used to correct for 231 population stratification (first three PCs, Figure S1 ) and cell type heterogeneity 21 . Samples 232 whose first PC (PC1) deviated more than 3 standard deviations from the mean PC1, were 233 excluded from analyses, reducing the final sample size from 665 to 636. In a sensitivity 234 analysis, associations were additionally adjusted for cell type proportions 24 . All analyses were 235 performed using R (version 3.4.3) using built-in functions unless otherwise specified. 236
We applied a Bonferroni threshold to correct for multiple testing. In the gene-based 237
GAMuT analysis, the significance threshold was adjusted for the number of tested genes 238 (threshold: 0.05/26,558 = 1.88 x 10 -6 ) and in the CpG-site-based linear regression analyses for 239 the number of tested CpG sites (threshold: 0.05/338,036=1.48 x 10 -7 ). 240
Methylation signals associated with cognitive decline were validated using CERAD 241
and Braak stage as outcomes. In addition, we analyzed whether the association between mediation analysis) by neuropathology (CERAD, Braak stage). Causal mediation analysis 244 from a counterfactual perspective was performed by using the R package "mediation" 39 , an 245 approach that relies on the quasi-Bayesian Monte Carlo method based on normal 246 approximation 40 . Using the counterfactual framework allows for definition of direct and 247 indirect effects and a total effect as the sum of direct and indirect effects. The indirect effect 248 refers to the effect through the mediator under study. The direct effect refers to the remaining 249 effect that is not through the mediator 41 . The proportion of the indirect effect in the total 250 effect was used to assess the extent to which the association between methylation and 251 cognitive decline was mediated through neuropathology as an intermediate pathway 42 . 252
The replication dataset did only have Braak stage as neurocognitive outcome, which is 253 strongly associated with cognitive decline 33 . In the replication dataset, associations between 254
CpG sites within a gene and the Braak stage were tested with GAMuT after correction for age 255 at death, sex and cell type composition. Due to the small sample size of the replication 256 dataset, we conducted a permutation test with 10,000 replications in addition to the Davies' 257 approximation to verify the accuracy of p-values. 258
The biological plausibility of our findings was examined by investigating the 259 association 1) of DNA methylation with gene expression as well as of gene expression with 260 cognitive decline and 2) of genotypes with cognitive decline to investigate if our associations 261 were due to a hidden genotype effect. All of these associations were tested using GAMuT and 262 the genotype associations were followed by a linear regression analysis on the single SNP 263 level. Fine-mapping of our epigenome-wide associations was done with coMET 43 , which is a 264 visualization tool of EWAS results with functional genomic annotations and estimation of co-265 methylation patterns. 266
267 Results 268
Description of study participants 269
There were 636 ROS/MAP participants included in this study with an average age at 270 death of 86 years and with 63% being female (Table 1) . Most of the participants were white 271 (98%), had a high level of education and 70% had never smoked. On average, cognitive 272 performance declined with age for every single domain (Table 1 ) and correlations of cognitive 273 decline between different domains were moderate, ranging from 0.54 to 0.78 (Table S1 ). 274
Cognitive decline was associated with more signs of neuropathology (CERAD and Braak 275 stage, Table S2 ). 276
There were 66 MRC Brain Bank participants with an average age at death of 87 years, 277 with 67% being female and an average Braak stage of 5 (Table 1) . 278
279
Methylation patterns of CLDN5 associated with cognitive decline 280
In the ROS/MAP participants (discovery dataset), we found that methylated CpG sites 281 in the Claudin-5 (CLDN5) locus were associated with cognitive trajectory (p-value = 9.96 x 282 10 -7 ; Figure 1 , Table 2, Table S3 , and Figure S1 ). This association was robust to adjustment 283 for cell type proportions (p-value = 8.52 x 10 -7 , Table S4 , Figures S2 and S3 ), to the selection 284 of a smaller window of CpG sites around each gene (p-value = 9.96 x 10 -7 , within 10kb, Table  285 S5), and to the restriction to participants with European ancestry (621/636 participants, p-286 value = 9.73 x 10 -7 , Table S6 ). The trajectories of episodic and working memory were the 287 main drivers for the observed association with both being associated with CpG sites assigned 288 to CLDN5 in the analyses of the single domains (Table 2, Figure S4 and Tables S7-S11). 289
Genes showing suggestive association with cognitive trajectory (p-values < 5 x 10 -5 ) included 290 AC084018.1, CTB-186G2.1, ATG16L2, KCNN4, RP11-779O18.1, TTC22, DCUN1D2-AS, 291 PNMA1 and RP11-101C11.1. The strongest associations with these genes were found with episodic memory, followed by working memory. Interestingly, most top methylation signals 293
in Table 2 (CLDN5 and 7/9 suggestive genes) were also at least nominally associated with 294 CERAD (Table 3, Figures S5-S6 and Table S12 ) and Braak stage (Table 3, Figure S7 and 295 Table S13 ). 296
To generalize our findings from the ROS/MAP participants, we performed the same 297 epigenetic analysis in MRC Brain Bank participants with DNA methylation data available 298 (replication dataset). We tested for differential methylation using Braak stage. Of the 8 299 methylation signals, which were at least nominally associated with Braak stage in the 300 discovery dataset, CLDN5, CTB-186G2.1 and KCNN4 could be replicated in the replication 301 dataset (Table 3 , Table S14, Figure S8 ). 302 303
Higher levels of methylation in CLDN5 locus associated with cognitive decline 304
To identify which CpG sites are the main drivers of the observed associations and to 305 understand the direction of association, we conducted a linear regression analysis for the 306 cognitive trajectory of each cognitive domain. Interestingly, except for PNMA1, higher levels 307 of methylation within our top genes were associated with an increased cognitive decline in 308 every single cognitive domain (Table S15 ). Within the CpG sites assigned to CLDN5, 309 cg16773741 and cg05460329 were the main drivers of the association with cg16773741 being 310 associated with episodic memory (p-value = 1.48 x 10 -8 ), semantic memory (8.81 x 10 -8 ) and 311 working memory (8.66 x 10 -9 ) ( Table 4 ). The direction of association with these two CpG 312 sites was consistent with the association observed for CERAD and Braak stage, which could 313 further be replicated in the replication dataset (Table S15, 
N=66). 314
To investigate if the association between methylation in CLDN5 and cognitive decline 317 is also present in participants without clear signs of neuropathology, we conducted an analysis 318 of the interaction between the most significantly associated CpG site (cg16773741) and 319 CERAD or Braak stage on cognitive decline. The association between methylation in 320 cg16773741 did not significantly differ between participants with no to little signs of 321 neuropathology versus participants with moderate to severe signs of neuropathology 322 (measured by CERAD and Braak stage; Figure 3) . Consequently, the association between 323 methylation in cg16773741 and decline in episodic, semantic, and working memory was even 324 significant in participants with no or little signs of neuropathology.. 325 326
Partial mediation through neuropathology 327
The association between DNA methylation in the CLDN5 locus (cg16773741) and 328 cognitive trajectory was only partially mediated through an increased neuropathology. It 329 ranged between 17% (95% confidence interval (CI): 18-40%) to 31% (95% CI: 18-61%) for 330 CERAD and 13% (95% CI: 7-21%) to 27% (95% CI: 15-41%) for Braak stage depending on 331 the cognitive domain ( Figure 4) . Therefore, the major part of the association with CLDN5 was 332 a direct association between methylation and cognitive decline, which was independent of 333 beta-amyloid and neurofibrillary neuropathology. 334
335
Methylation signals were independent of genotypes 336
Genotypes located within the windows of CLDN5 were associated with DNA 337 methylation (p-value < 10 -6 ), but not with cognitive trajectory (p-value = 0.4415, Table S16 338 A). In line, associations of DNA methylation in the CLDN5 window with cognitive trajectory This observation was confirmed by the subsequent analyses on the single CpG / SNP 341 level, which showed that the CpG sites associated with genotypes were not the same as being 342 associated with cognitive trajectory (Table S17, Figure 2 and Figures S9 to S12). This 343 indicates that our methylation signals were not caused by hidden genotype effects. 344
345
No clear association with gene expression levels 346
In our sample, we find no association between DNA methylation in the CLDN5 347 window and CLDN5 expression (p-value = 0.1978; Table S17 ). KCNN4 was the only top gene 348 (Table 2) for which methylation levels were associated with expression levels (p-value = 349 0.0004; Table S18 ). Furthermore, cognitive trajectory was not associated with expression of 350 any gene in Table 2 (Table S18) . 351
352
Discussion 353
In this study, we found an epigenome-wide association between brain-tissue-based 354 DNA methylation in the CLDN5 locus and cognitive trajectory in more than 600 participants 355 from the ROS/MAP cohort. This association was significant across different domains and 356 particularly associated with trajectories in episodic and working memory. We also found that 357 higher levels of methylation in CLDN5 were associated with neuropathology in our discovery 358 and replication datasets consistent with the direction of association found with cognitive 359 decline. Most interestingly, the association between methylation in CLDN5 and cognitive 360 decline was independent of beta-amyloid and neurofibrillary neuropathology and even present 361 in participants with low levels of those pathologies. In addition, only 13-31% of the 362 association between methylation and cognitive decline was mediated through levels of 363 neuropathology, whereas the major part of the association was independent of it. Finally, we found no evidence that hidden effects of genotypes in the CLDN5 locus confounded our 365 methylation results. 366 CLDN5 is an integral membrane protein and an important component of tight junction 367 protein complexes that comprise the blood-brain barrier. The blood-brain barrier is located at 368 endothelial cells lining the brain microvasculature and is maintained by the neurovascular 369 unit, a functional relationship between astrocytes, neurons, and endothelial cells 44 . 370
Dysfunction of the blood-brain barrier has been implicated in neurodegenerative disorders, 371 such as AD 44-47 . Thus, our finding that altered regulation of CLDN5 is associated with 372 cognitive decline suggests a role of blood-brain barrier dysfunction in cognitive decline. We 373 note that an estimated two-thirds of AD dementia (clinically defined) and that an estimated 374 40% of cognitive decline are attributable to known age-related neuropathologies 4,48 . Thus, 375 our findings may account for some of the unaccounted-for variation in cognitive decline and 376 AD dementia. 377 This is the first epigenome-wide study using cognitive trajectory in older individuals. 378
A previous study on the same cohort showed an association of 71 CpG sites with neuritic 379 plaque burden, of which 11 were validated in an independent cohort 11 . Here, we showed that 380 all of these 11 signals were at least nominally associated with cognitive trajectory and the 381 strongest associations were again found for cognitive trajectory of episodic and working 382 memory (Table S19 ). In addition, we identified methylation in CLDN5 as new epigenetic 383 factor associated with cognitive trajectory, a gene that has not been linked to AD in a 384 population-based cohort. 385
By contrast, associations of blood-based methylation levels with global cognitive 386 function (cg21450381) and phonemic verbal fluency (cg12507869) 15 could not be validated 387 in our study (Table S20 ). The likely reasons are the different source of methylation data, and 388 differences in the phenotype (i.e., cognitive trajectory over time in our study versus cognitive 389 testing at a single time point 15 ). 390
Strengths of this study include the ROS/MAP cohort as a discovery dataset which is 391 notable for its longitudinal nature with very high follow-up rates, prospective collection of 392 data, a community-based cohort design, and detailed neuropathological examination 393 following high autopsy rates. The validity of our signals was also determined in an 394 independent replication dataset, and the availability of genomic data allowed us to determine 395 methylation changes were not the result of hidden genotype effect. This study is also 396 strengthened by the GAMuT 16 statistical method that harnesses correlations among cognitive 397 domains and among CpG sites to improve statistical power compared to standard univariate 398
techniques. 399
The study is potentially limited by its cross-sectional nature. Although brain tissue is 400 the ideal target tissue to measure DNA methylation related to cognitive trajectory, it inhibited 401 a simultaneous (or even later) assessment of cognitive function. Consequently, we cannot 402 exclude the potential risk of reverse causality in our associations. Another potential limitation 403 is the use of bulk tissue analysis which might obscure signals from different cell populations. 404
This problem was mitigated in our analysis by adjusting for cell-type composition. However, 405 the bulk tissue analysis may have obscured an association between CLDN5 methylation and 406
RNA expression. Future studies should investigate the role of CLDN5 in specific cell types 407 from brain and investigate whether there is a causal relationship between CLDN5 408 dysregulation and cognitive decline in animal models of AD. 409
In conclusion, we have presented evidence for brain-based DNA methylation in 410 association with cognitive trajectory. We identified methylation in CLDN5 as a new 411 epigenetic factor associated with cognitive trajectory, which was validated in an independent 412 dataset and independent of beta-amyloid and neurofibrillary neuropathology. Higher levels of 413 methylation in CLDN5 were associated with cognitive decline implicating the blood brain 414 barrier in maintenance of cognitive trajectory with aging. . EM: decline in episodic memory; PS: decline in perceptual speed; PO: decline in perceptual orientation; SM: decline in semantic memory; WM: decline in working memory. Adjusted for age at death, education, sex, ancestry, smoking status, post-mortem interval (PMI) and the first four principal components. sites and cognitive decline in ROS/MAP (discovery dataset) adjusted for age at death, 10 education, sex, ancestry, smoking status, post-mortem interval (PMI) and the first four 11 principal components. The most significant CpG site (cg16773741) is marked in purple and 12
Figure Legends
CpG sites associated with genotypes in the same window are marked in yellow (compare 13 Table S17 ). which is mediated through neuropathology (CERAD & Braak stage) is given in percent. EM: 33 decline in episodic memory; PS: decline in perceptual speed; PO: decline in perceptual 34 orientation; SM: decline in semantic memory; WM: decline in working memory. Adjusted for 35 age at death, education, sex, ancestry, smoking status, post-mortem interval (PMI) and the 36 first three principal components (PCs). 37 38
